TOLMEN`S LABYRINTH FOR THE DEVELOPMENT OF AN EXPERIMENTAL MODEL OF BRAIN PATHOLOGY IN MICE IN THE STUDY OF POLYMER MUCOADHESIVE DOSAGE FORMS
Introduction: A promising direction for improving bioavailability in brain tissues is the use of water-soluble polymers for intranasal use. Due to the direct communication through the lattice bone of the nasal cavity with the brain, it became necessary to study water-soluble polymers on the nasal mucosa.
Objective: To conduct a study of modeling brain pathology for the study of polymer mucoadhesive dosage forms in mice by round-the-clock monitoring of behavior in a maze.
Methods: Violations of cognitive functions of the brain in experimental groups were studied on experimental mice: with passage through a maze with preliminary training, passage through a maze after the use of inhaled anesthesia of Isoflurane.
Results: The severity of CNS disorders in the two experimental groups with the use of Isoflurane was different. After waking up, all mice in the control group showed a decrease in motor activity, an increase in the time to overcome the maze and a directly proportional dependence of the duration of sleep on the dose of the injected Isoflurane solution. The weight of experimental mice affects the time of passage through the maze in 100% of cases. The dose of toxic effects of Isoflurane on mice corresponding to 17 drops has been established. Analysis of all data showed in the experimental group of mice in 90% of cases, with an increase in the dose of Isoflurane, the time to overcome the maze increased exponentially. In 2 cases (10%) after waking up in a maze, there was no decrease in the motor activity of mice. The experimental group with a preliminary acquaintance of the maze had a picture different from the one in which there was no acquaintance. Despite the rapid adaptation of mice in the environment, during the first 2-3 minutes the mice moved slowly. Compared with the group without prior acquaintance, a decrease in motor activity in the new conditions after the use of Isoflurane and the duration of the time of overcoming through the maze was noted in 80% of cases and the average time was 980 seconds, whereas in the experimental group with preliminary acquaintance this value was 193 seconds.
Conclusions: Tolman's labyrinth allows us to assess the level of cognitive impairment of the brain in mice and the time to overcome it to serve as a basic criterion. The body weight of mice influences the time of passage through the maze (p=0.008).
Аltynay Talgatkyzy1,
TalgatN. Khaybullin1, https://orcid.org/0000-0003-1886-0538
Elvira К. Ozhmukhametova2, https://orcid.org/0000-0001-5963-855X
Мaksut S. Kazymov1, https://orcid.org/0000-0002-7763-3960
1 NCJSC "Semey Medical University", Semey c., Republic of Kazakhstan;
2 SUC on the REM «City multifunctional hospital №2» Akimat of Nur-Sultan, Republic of Kazakhstan.
1. Ahterov A.V., Barbashova T.F., Belousov A.I., Bobik A.A. i dr. K voprosu o modelirovanii dvigatel'nogo povedenya krys v mnogoal'ternativnom Zh-obraznom labirinte // Moskva. 2008. S.
2. Al-Shahi Salman R., Law Z.K., Bath P.M.W., Steiner T., SpriggN.Haemostatic therapies for acute spontaneous intracerebralhaemorrhage //Cochrane Database Syst. Rev. // 2018.№4: CD005951.
3. Aulton M.E., Pharmaceutics: The Science of Dosage Form Design, 2nd edition, Churchill Livingstone, Edinburgh 2020.
4. Barnes G., Piazza G., Chao Tze-Fan, Zimerman L. Barriers to stroke prevention in Atrial Fibrillation: Insights from the global anticoagulation Roundtable // Inter Jour Clin Heart & Vasculature. 2022. №2. Vol.45. DOI: 10.1016/j.ijcha.2022.101096.
5. Belenichev I.F.,Buhtijarova N.V., Pavlov S.V., Ryzhenko V.P. Farmakokineticheski monitoring lekarstvennyh sredstv // Uchebnoe posobie dlya magistrov, Zaporozh'e. – 2018. 175p.
6. Еticheskie problemy, svjazannye s provedeniem eksperimentov na zhivotnyh. «Hel'sinskaya deklaracya» Vsemirnya medicinskaya associaciya -1964. Uchebnoe posobie.
7. Feigin V.I., Lawes C.M., Bennett D.A., Barker-Collo S.I., Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systemic review//Lancet Neurol 2009.№8. P. 355-69.
8. Florence A.T., Attwood D., Physicochemical Principles of Pharmacy, 3rd edition, Palgrave, Basingstoke. - 2018. 210 p.
9. Gal'perin P.Ja., Zhdan L.I. Kognitivnye karty u krysi u cheloveka. Izdatel'stvo Moskva. 2019. S.160-82.
10. Inoue D., Yamashita A., To H. Formulation and in vitro characterization of a vacuum-dried drug–polymer thin film for intranasal application // Journ Polymers. №14. P.2954. DOI: 10.3390/polym14142954
11. KrzyszczakA., DybowskiP. Michal, Kończak M., Czech B. Low bioavailability of derivatives of polycyclic aromatic hydrocarbons in biochar obtained from different feedstock // Environmental Research. 2022. Vol.214(Pt 1). DOI: 10.1016/j.envres.2022.113787
12. Lattanzi S., Cagnetti C., Provinciali L., Silvestrini M. How should we lower blood pressure after cerebral hemorrhage? A systematic review and meta-analysis //CerebrovascularDis. 2017. Vol.43. P. 207–13.
13. Livesay S. Sarah., Casper C., Graves A., Wilson S.et al.Abstract WP396: Barriers to Stroke Coordinator Practice // Stroke ISSN: 1524-4628. 2017. №48. Supply1. DOI: 10.1161/str.48.suppl_1. wp396.
14. Luo Y., Wang Y., Fu J. Nanomaterials in cerebrovascular disease diagnose and treatment // Particle and particle systems characterization. 2021. №5. Vol.38.p.317-19. DOI: 10.1002/ppsc.202000311
15. Manzoor Ahmad Mir Natural medicine in cerebrovascular diseases // Dilpreet Publishers. 2019. New Delhi. India. ISBN-978-93-85497-940. Vol. 1. P.1-102.
16. Miyawaki S., Imai Hideaki., Saito Nobuhito: Precision Medicine for Ischemic Cerebrovascular Diseases // Japanese Journal of Neurosurgery. 2018.- №27(7). P.528-38.
17. Nacional'naya associacya o bor'be s insul'tom. Ishemicheski insul't i tranzitornaya ishemicheskaya ataka u vzroslyh. Klinicheskie rekomendacii I63/G45/G46. 2020. S.70-74.
18. Panwar A., Veeramalla M., Vallupadas C., Muriki R. Barriers to stroke thrombolysis// Journal of Clinical and Diagnostic Researc. 2017. №12. Vol.11. pp. 101-05. DOI: 10.7860/JCDR/2017/31815.10919.
19. Porfiryeva N.N., Semina I.I., Moustafine R. I, Khutoryanskiy V.V. Intranasal Administration as a Route to Deliver Drugs to the Brain (Review) // Drug Development &Registration. 2021.№4. Vol.10. P.117-27.
20. Tabeeva G. R.Headache and cerebrovascular diseases // Journal Neurology and Psychiatry named after KorsakovS.S. 2021. №2. Vol.121. P.114.DOI: 10.17116/jnevro2021121021114.
21. Valuev I.L., Gorshkova M., Vanchugova L.V., ValuevL.I. Mucoadhesive Polymer Carriers of Intranasal Medicines // Journ Polymer Science Series A. 2019. №3 (63). P. 287-91.
22. Venkat P., Choop M. Exosome treatment for stroke with diabetic comorbidity // Journal Neural Regeneration Research. 2022. №2. Vol. 17. P. 315.
Number of Views: 90
Category of articles:
Original articles
Bibliography link
Talgatkyzy А., Khaybullin T.N., Ozhmukhametova E.К., Kazymov М.S. Tolmen`s labyrinth for the development of an experimental model of brain pathology in mice in the study of polymer mucoadhesive dosage forms // Nauka i Zdravookhranenie [Science &Healthcare]. 2022, (Vol.24) 5, pp.141-148. doi 10.34689/SH.2022.24.5.018Related publications:
ANALYSIS OF CLINICAL AND DEMOGRAPHIC INDICATORS OF PATIENTS WITH PARKINSON'S DISEASE IN THE SOUTHERN REGION OF KAZAKHSTAN
A COMPARATIVE STUDY OF DRUG POLICY REGARDING ORPHAN DISEASES IN THE USA, THE EUROPEAN UNION, AND THE REPUBLIC OF KAZAKHSTAN
MUTATIONS IN CARDIAC ION CHANNEL GENES IN KAZAKHSTANI PATIENTS WITH LONG QT SYNDROME
GENETIC FEATURES OF CONGENITAL DYSFUNCTION OF THE ADRENAL CORTEX CAUSED BY 21-HYDROXYLASE DEFICIENCY IN PERSONS OF KAZAKH NATIONALITY
NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE USING THE EXAMPLE OF AKTOBE PATIENTS